Abstract
Ferroptosis is an iron-dependent form of regulated cell death driven by the lethal accumulation of lipid peroxides. System $x_c^-$, a heterodimeric amino acid transporter composed of xCT (SLC7A11) and 4F2hc (SLC3A2), is a critical regulator of this process, mediating the uptake of cystine required for glutathione synthesis. Erastin is a well-known small molecule that induces ferroptosis by inhibiting system $x_c^-$, yet the structural basis for this inhibition has remained elusive. This study presents the 3.4 Å cryo-electron microscopy (cryo-EM) structure of the human xCT–4F2hc complex bound to erastin, identifying the specific molecular interactions that allow erastin to block cystine transport and providing a blueprint for the development of improved ferroptosis-inducing therapeutics.
Introduction
Targeting ferroptosis has emerged as a promising strategy in oncology, particularly for treating therapy-resistant cancers. System $x_c^-$ serves as the primary cellular defense against oxidative stress by providing the raw materials for antioxidant production. Erastin, while a potent tool for inducing ferroptosis in vitro, suffers from poor pharmacological properties. Understanding the precise binding mode of erastin within the xCT transporter is essential for designing more stable and potent analogs, such as Imidazole Ketone Erastin (IKE).
Structural Architecture of the xCT–4F2hc Complex
Using cryo-EM, the researchers determined the structure of the human xCT–4F2hc complex at a resolution of 3.4 Å. The complex was captured in an inward-facing conformation, where the intracellular vestibule of the xCT subunit is open to the cytoplasm. A key structural feature distinguishing xCT from its close relative LAT1 is the flexibility of the TM6b domain. In xCT, this region transitions from a rigid helix to a flexible loop, creating a unique pocket that accommodates the erastin molecule.
The Molecular Mechanism of Erastin Inhibition
Erastin acts as a molecular "plug," binding deep within the intracellular vestibule of xCT. This binding effectively traps the transporter in the inward-facing state, preventing the conformational changes necessary to transport cystine across the membrane.
Key molecular interactions identified include:
- Phe254 Anchor: The benzene ring of erastin engages in a critical stacking interaction with the Phe254 residue of xCT. Mutating this residue (F254A) significantly reduced erastin's inhibitory effect.
- Gln191 and Phe336: These residues also contribute to the stability of the binding pocket. Interestingly, mutations like Q191A and F336A increased cellular sensitivity to erastin, likely by destabilizing the transporter's native function.
- IKE Potency: Molecular docking suggests that the analog IKE occupies the same primary pocket as erastin but extends into an additional sub-pocket formed by Tyr251, Ala247, Lys198, and Ser330. This additional "grip" explains IKE's superior potency in inducing ferroptosis.
Functional Validation and Resistance
The structural findings were validated through extensive site-directed mutagenesis and cellular assays. In HT-1080 fibrosarcoma cells, the F254A mutation increased the $IC_{50}$ of erastin from 1.6 $\mu$M to 18.8 $\mu$M, demonstrating a nearly 12-fold increase in resistance. Functional assays using radioactive $^{14}\text{C}$-labeled cystine confirmed that erastin directly blocks the uptake of its substrate, leading to a depletion of cellular antioxidants and subsequent lipid peroxidation, as measured by C11-BODIPY fluorescence.
Conclusion
By providing the first high-resolution map of the erastin-binding site, this study clarifies the molecular basis of system $x_c^-$ inhibition. The identification of the Phe254-dependent pocket and the structural plasticity of TM6b offers a clear path for the rational design of next-generation ferroptosis inducers with improved clinical potential. While erastin itself may not be a viable drug, the structural insights gained here pave the way for more effective cancer treatments targeting the metabolic vulnerabilities of tumor cells.
Summary updated